Genomtec Statistics

Total Valuation

Genomtec has a market cap or net worth of PLN 101.69 million. The enterprise value is 90.43 million.

Market Cap	101.69M
Enterprise Value	90.43M

Important Dates

The last earnings date was Thursday, May 29, 2025.

Earnings Date	May 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Genomtec has 14.87 million shares outstanding. The number of shares has increased by 17.25% in one year.

Current Share Class	14.87M
Shares Outstanding	14.87M
Shares Change (YoY)	+17.25%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	9.11%
Owned by Institutions (%)	4.98%
Float	11.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16,948.52
PB Ratio	6.70
P/TBV Ratio	6.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.69
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.17.

Current Ratio	3.08
Quick Ratio	2.90
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-504.96

Financial Efficiency

Return on equity (ROE) is -112.95% and return on invested capital (ROIC) is -57.48%.

Return on Equity (ROE)	-112.95%
Return on Assets (ROA)	-35.31%
Return on Invested Capital (ROIC)	-57.48%
Return on Capital Employed (ROCE)	-61.94%
Revenue Per Employee	231
Profits Per Employee	-452,115
Employee Count	26
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

In the past 12 months, Genomtec has paid 54,000 in taxes.

Income Tax	54,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.29% in the last 52 weeks. The beta is 0.23, so Genomtec's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-39.29%
50-Day Moving Average	7.34
200-Day Moving Average	7.62
Relative Strength Index (RSI)	38.35
Average Volume (20 Days)	11,652

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genomtec had revenue of PLN 6,000 and -11.76 million in losses. Loss per share was -0.79.

Revenue	6,000
Gross Profit	-634,000
Operating Income	-11.61M
Pretax Income	-11.70M
Net Income	-11.76M
EBITDA	-9.29M
EBIT	-11.61M
Loss Per Share	-0.79

Full Income Statement

Balance Sheet

The company has 13.84 million in cash and 2.58 million in debt, giving a net cash position of 11.26 million or 0.76 per share.

Cash & Cash Equivalents	13.84M
Total Debt	2.58M
Net Cash	11.26M
Net Cash Per Share	0.76
Equity (Book Value)	15.17M
Book Value Per Share	1.02
Working Capital	10.72M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-193,566.67%
Pretax Margin	-195,016.67%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Genomtec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.25%
Shareholder Yield	n/a
Earnings Yield	-11.56%
FCF Yield	n/a

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genomtec has an Altman Z-Score of 4.01 and a Piotroski F-Score of 1.

Altman Z-Score	4.01
Piotroski F-Score	1